tiprankstipranks
Trending News
More News >
Lemaitre Vascular (LMAT)
NASDAQ:LMAT
US Market

Lemaitre Vascular (LMAT) Stock Forecast & Price Target

Compare
230 Followers
See the Price Targets and Ratings of:

LMAT Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Lemaitre
Vascular
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LMAT Stock 12 Month Forecast

Average Price Target

$111.86
▲(2.44% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Lemaitre Vascular in the last 3 months. The average price target is $111.86 with a high forecast of $124.00 and a low forecast of $94.00. The average price target represents a 2.44% change from the last price of $109.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","102":"$102","125":"$125","90.5":"$90.5","113.5":"$113.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,90.5,102,113.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.395,108.67230769230768,109.94961538461538,111.22692307692307,112.50423076923077,113.78153846153846,115.05884615384615,116.33615384615385,117.61346153846154,118.89076923076922,120.16807692307692,121.44538461538461,122.72269230769231,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.395,107.73846153846154,108.08192307692308,108.42538461538462,108.76884615384616,109.1123076923077,109.45576923076923,109.79923076923076,110.1426923076923,110.48615384615384,110.82961538461538,111.17307692307692,111.51653846153846,{"y":111.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.395,106.36461538461538,105.33423076923077,104.30384615384615,103.27346153846153,102.24307692307693,101.21269230769231,100.18230769230769,99.15192307692308,98.12153846153846,97.09115384615384,96.06076923076924,95.03038461538462,{"y":94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.037,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.004,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.583,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.629,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.048,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.324,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.686,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.145,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.395,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$111.86Lowest Price Target$94.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on LMAT
Citizens JMP
Citizens JMP
$113$118
Buy
8.06%
Upside
Reiterated
02/26/26
LeMaitre price target raised to $118 from $113 at CitizensLeMaitre price target raised to $118 from $113 at Citizens
Sidoti
$124
Buy
13.55%
Upside
Reiterated
02/26/26
Sidoti Keeps Their Buy Rating on Lemaitre Vascular (LMAT)
Barrington Analyst forecast on LMAT
Barrington
Barrington
$95$105
Buy
-3.85%
Downside
Reiterated
02/26/26
LeMaitre price target raised to $105 from $95 at BarringtonLeMaitre price target raised to $105 from $95 at Barrington
Wells Fargo Analyst forecast on LMAT
Wells Fargo
Wells Fargo
$87$94
Hold
-13.92%
Downside
Reiterated
02/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: MannKind (NASDAQ: MNKD), Lemaitre Vascular (NASDAQ: LMAT) and Alkermes (NASDAQ: ALKS)
Stifel Nicolaus Analyst forecast on LMAT
Stifel Nicolaus
Stifel Nicolaus
$115
Buy
5.31%
Upside
Reiterated
02/26/26
Stifel Nicolaus Sticks to Their Buy Rating for Lemaitre Vascular (LMAT)
Lake Street Analyst forecast on LMAT
Lake Street
Lake Street
$110
Buy
0.73%
Upside
Reiterated
02/26/26
Lake Street Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
KeyBanc
Hold
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT) and Revolution Medicines (NASDAQ: RVMD)
Roth MKM Analyst forecast on LMAT
Roth MKM
Roth MKM
$108$117
Buy
7.14%
Upside
Reiterated
02/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Alkermes (NASDAQ: ALKS) and Lemaitre Vascular (NASDAQ: LMAT)
Oppenheimer Analyst forecast on LMAT
Oppenheimer
Oppenheimer
Hold
Reiterated
11/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), MBX Biosciences, Inc. (NASDAQ: MBX) and Lemaitre Vascular (NASDAQ: LMAT)
Cantor Fitzgerald Analyst forecast on LMAT
Cantor Fitzgerald
Cantor Fitzgerald
$95
Hold
-13.00%
Downside
Reiterated
08/11/25
Cantor Fitzgerald Sticks to Their Hold Rating for Lemaitre Vascular (LMAT)
Jefferies Analyst forecast on LMAT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on LMAT.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on LMAT
Citizens JMP
Citizens JMP
$113$118
Buy
8.06%
Upside
Reiterated
02/26/26
LeMaitre price target raised to $118 from $113 at CitizensLeMaitre price target raised to $118 from $113 at Citizens
Sidoti
$124
Buy
13.55%
Upside
Reiterated
02/26/26
Sidoti Keeps Their Buy Rating on Lemaitre Vascular (LMAT)
Barrington Analyst forecast on LMAT
Barrington
Barrington
$95$105
Buy
-3.85%
Downside
Reiterated
02/26/26
LeMaitre price target raised to $105 from $95 at BarringtonLeMaitre price target raised to $105 from $95 at Barrington
Wells Fargo Analyst forecast on LMAT
Wells Fargo
Wells Fargo
$87$94
Hold
-13.92%
Downside
Reiterated
02/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: MannKind (NASDAQ: MNKD), Lemaitre Vascular (NASDAQ: LMAT) and Alkermes (NASDAQ: ALKS)
Stifel Nicolaus Analyst forecast on LMAT
Stifel Nicolaus
Stifel Nicolaus
$115
Buy
5.31%
Upside
Reiterated
02/26/26
Stifel Nicolaus Sticks to Their Buy Rating for Lemaitre Vascular (LMAT)
Lake Street Analyst forecast on LMAT
Lake Street
Lake Street
$110
Buy
0.73%
Upside
Reiterated
02/26/26
Lake Street Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
KeyBanc
Hold
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT) and Revolution Medicines (NASDAQ: RVMD)
Roth MKM Analyst forecast on LMAT
Roth MKM
Roth MKM
$108$117
Buy
7.14%
Upside
Reiterated
02/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Alkermes (NASDAQ: ALKS) and Lemaitre Vascular (NASDAQ: LMAT)
Oppenheimer Analyst forecast on LMAT
Oppenheimer
Oppenheimer
Hold
Reiterated
11/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), MBX Biosciences, Inc. (NASDAQ: MBX) and Lemaitre Vascular (NASDAQ: LMAT)
Cantor Fitzgerald Analyst forecast on LMAT
Cantor Fitzgerald
Cantor Fitzgerald
$95
Hold
-13.00%
Downside
Reiterated
08/11/25
Cantor Fitzgerald Sticks to Their Hold Rating for Lemaitre Vascular (LMAT)
Jefferies Analyst forecast on LMAT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on LMAT.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lemaitre Vascular

3 Months
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+9.21%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +9.21% per trade.
1 Year
Daniel StauderCitizens JMP
Success Rate
6/9 ratings generated profit
67%
Average Return
+29.03%
reiterated a buy rating 15 days ago
Copying Daniel Stauder's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +29.03% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
89%
Average Return
+41.69%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +41.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LMAT Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Dec 25
Feb 26
Mar 26
Strong Buy
0
0
0
0
0
Buy
24
18
17
13
13
Hold
6
9
10
10
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
27
27
23
16
In the current month, LMAT has received 13 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LMAT average Analyst price target in the past 3 months is 111.86.
Each month's total comprises the sum of three months' worth of ratings.

LMAT Financial Forecast

LMAT Earnings Forecast

Next quarter’s earnings estimate for LMAT is $0.66 with a range of $0.64 to $0.68. The previous quarter’s EPS was $0.68. LMAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.
Next quarter’s earnings estimate for LMAT is $0.66 with a range of $0.64 to $0.68. The previous quarter’s EPS was $0.68. LMAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.

LMAT Sales Forecast

Next quarter’s sales forecast for LMAT is $66.57M with a range of $65.60M to $67.10M. The previous quarter’s sales results were $64.45M. LMAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.
Next quarter’s sales forecast for LMAT is $66.57M with a range of $65.60M to $67.10M. The previous quarter’s sales results were $64.45M. LMAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.

LMAT Stock Forecast FAQ

What is LMAT’s average 12-month price target, according to analysts?
Based on analyst ratings, Lemaitre Vascular’s 12-month average price target is 111.86.
    What is LMAT’s upside potential, based on the analysts’ average price target?
    Lemaitre Vascular has 2.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LMAT a Buy, Sell or Hold?
          Lemaitre Vascular has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Lemaitre Vascular’s price target?
            The average price target for Lemaitre Vascular is 111.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $94.00. The average price target represents 2.44% Increase from the current price of $109.2.
              What do analysts say about Lemaitre Vascular?
              Lemaitre Vascular’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of LMAT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.